Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Clin Cancer Res. 2018 Feb 20;24(10):2408–2416. doi: 10.1158/1078-0432.CCR-17-3474

Figure 3. Efficacy of ADT and VTP combination in the VCaP human prostate cancer model.

Figure 3

SCID mice bearing VCaP tumors were randomly assigned to 4 cohorts: control (n=7), degarelix (n=9), VTP (n=8), degarelix + VTP (n=9) and tumor size was measured weekly. One dose of degarelix was given 3 days prior to VTP treatment. Combination therapy led to superior local tumor control compared to monotherapy (p<0.0001 for degarelix, p<0.005 for VTP).